The Impact of Biosimilars in Supportive Care in Cancer-Reference-Cited by-同舟云学术

The Impact of Biosimilars in Supportive Care in Cancer

Published:2018 Issue:1 Volume:14 Page:20
ISSN:2045-5275
Container-title:European Oncology & Haematology
language:en
Short-container-title:

Author:

Cornes Paul¹,Aapro Matti²

Affiliation:

1. Comparative Outcomes Group, Bristol, UK

2. Multidisciplinary Oncology Institute, Clinique de Genolier, Genolier, Switzerland

Abstract

Funder

No funding was received in relation to the publication of this article.

Publisher

Touch Medical Media, Ltd.

Subject

Oncology,Hematology

Reference174 articles.

1. Cornes P. The economic pressures for biosimilar drug use in cancer medicine.Target Oncol. 2012;7:S57–67.

2. de Mora F. Biosimilar: what it is not.Br J Clin Pharmacol. 2015;80:949–56.

3. World Health Organization. Expert Committee on Biological Standardization. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs), 2009. Available at: www.who.int/biologicals/areas/biological_therapeutics/BıOTHERAPEUTıCS_FOR_WEB_22APRıL2010.pdf (accessed 1 December 2017).

4. US Food & Drug Administration. ınformation on Biosimilars, 2017. Available at: www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm (accessed 1 December 2017).

5. Health Canada. Fact-sheet: Biosimilars, 2003. Available at: www.hcsc.gc.ca/dhp-mps/brgtherap/applic-demande/guides/biosimilarsbiosimilaires- qa-qr-eng.php (accessed 1 December 2017).

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanism of Biosimilars for the Treatment of Cancer;Biosimilars for Cancer Treatment;2024

2. Biosimilars in Oncology: Latest Trends and Regulatory Status;Pharmaceutics;2022-12-05

4. Biosimilars in supportive care;Current Opinion in Oncology;2020-05-13

5. A consensus statement on the use of biosimilar medicines in hematology in Australia;Asia-Pacific Journal of Clinical Oncology;2020-04-14